Editas Medicine, Inc.

Editas Medicine, Inc.

Editas Medicine, Inc.

Overview
Date Founded

2013

Headquarters

11 Hurley Street,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

208

Industries

Biotechnology
Hospitals & Patient Services
Medical Support Services

Company Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Editas Medicine, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman, President & Chief Executive Officer

Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Secretary

Senior Vice President & Chief Legal Officer

Chief Human Resources Officer

Chief Business Officer

Executive Vice President & Chief Medical Officer

Senior Vice President, Operations

Vice President, Technical Development & Manufacturing

Scientific Founder

Scientific Founder

Board of Directors

Chairman, President & Chief Executive Officer at Editas Medicine, Inc.

Co-Founder at Fate Therapeutics, Inc.

Founder at J Hopfield Consulting

President-Research & Development at Alnylam Pharmaceuticals, Inc.

Entrepreneur at Polaris Partners

President, Chief Executive Officer & Director at C4 Therapeutics, Inc.

Senior Vice President-Global Business Development at Legend Biotech Corp.

Paths to Editas Medicine, Inc.
Potential Connections via
Relationship Science
You
Editas Medicine, Inc.
Owners & Shareholders
Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Details Hidden

Nikko AMA offers both active and passive investment capabilities across equity, fixed income and alternative asset classes, with key strengths in multiple-pan-Asian asset strategies. Equity analysts are assigned responsibilities based on geographic regions, sectors or investment styles. The firm’s general approach focuses on fundamental bottom-up analysis; although it will vary depending on specific requirements of the investment strategy pursued and is tailored accordingly. Nikko AMA also provides broad coverage of global fixed income markets and currencies with consideration to the following factors: Macro Fundamentals, Interest Rates, Market Liquidity, and Investor Positioning/Relative Performance.

Details Hidden

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm’s strategies include core international/emerging market equities, international equity, international small- and mid-cap equity, balanced/asset allocation, managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large-cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Recent Transactions
Details Hidden

Editas Medicine, Inc. issued USD Common Stock

Details Hidden

Editas Medicine, Inc. issued USD Common Stock

Details Hidden

Editas Medicine, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onEditas Medicine, Inc. issued USD Common Stock

Underwriter

Advised onEditas Medicine, Inc. issued USD Common Stock

Legal Advisor

Advised onEditas Medicine, Inc. issued USD Common Stock

Underwriter

Advised onEditas Medicine, Inc. issued USD Common Stock

Underwriter

Advised onEditas Medicine, Inc. issued USD Common Stock

Associate

Advised onEditas Medicine, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Entrepreneur at Polaris Partners

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Key Stats and Financials As of 2019
Market Capitalization
$3.74B
Total Enterprise Value
$1.05B
Earnings Per Share
$-2.68
Revenue
$20.5M
Net Profit
$-134M
Total Equity
$262M
EBITDAMargin
-672.6%
EBITDA
$-138M
Total Debt
$29.1M
Enterprise Value / Sales
51.24x
TEVNet Income
-7.87x
Debt TEV
0.03x
Three Year Compounded Annual Growth Rate Of Revenue
50.25%
Non-Profit Donations & Grants
$10K - $25K
2017
Investors
Details Hidden

FMR help over 32 million people feel more confident in their most important financial goals, manage employee benefit programs for over 22,000 businesses, and support more than 13,000 financial institutions with innovative investment and technology solutions to grow their businesses.

Details Hidden

Casdin Capital / Private Equity/ invests in companies located in the US. The firm targets companies operating in the fields of life sciences and healthcare industry. It provides financing for early stage capital requirement

Details Hidden

Deerfield Management Co. LP invests in companies located in the US. The firm target companies operating in broad range of industries. They provides financing for buyout transactions to private and public.

Suppliers
Harvard University Schools & Student Services | Cambridge, MA

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

The Broad Institute, Inc. Medical Support Services | Cambridge, MA

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Mass General Brigham, Inc. Social Interest | Boston, MA

Mass General Brigham, Inc. engages in the provision of patient care, research, teaching, and community services. It offers community and specialty hospitals, physician network, community health centers, and home care. The firm also sponsors research programs and community health outreach programs. The company was founded in 1994 and is headquartered in Boston, MA.

Competitors
Vertex Pharmaceuticals, Inc. Pharmaceuticals - Boston, MA

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Intellia Therapeutics, Inc. Biotechnology - Cambridge, MA

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Editas Medicine, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Editas Medicine, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Editas Medicine, Inc..